A Therapeutic Update on the Management of Patients with Atopic Dermatitis
After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.
The goal of this activity is to provide up-to-date comprehensive information for clinicians on the treatment and management of patients with AD.
This enduring activity is intended for dermatologists, allergists, immunology specialists, internists and primary care providers, including physicians, nurse practitioners, physician assistants, and other healthcare providers who are responsible for the diagnosis, treatment, or management of patients with AD. No prerequisites required.
Upon completion of this activity, participants will be better able to do the following:
- Evaluate the current standard of care for treating AD and its limitations in treating moderate-to-severe AD.
- Describe key immune pathways associated with AD and the role of these pathways in treatment development.
- Integrate the latest information on new and emerging advancements in the treatment of patients with AD.
Lawrence Eichenfield, MD (Chair)
Jonathan I. Silverberg, MD, PhD, MPH
Linda Stein-Gold, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Lawrence Eichenfield, MD
Speakers’ Bureau: Valeant
Consultant/Advisor: Allergan; Anacor Pharmaceuticals Inc; Dignity Sciences Ltd.; Eli Lilly and Company; Galderma; Genentech, Inc.; Otsuka Pharmaceutical Co., Ltd/Medimetriks Pharmaceuticals Inc; Pfizer Inc; Ralexar Therapeutics; Regeneron Pharmaceuticals, Inc; TopMD Inc; Valeant
Grant/Research Support: Regeneron Pharmaceuticals, Inc
Jonathan I. Silverberg, MD, PhD, MPH
Speakers’ Bureau: Regeneron Pharmaceuticals, Inc
Consultant/Advisor: AbbVie Inc; Anacor Pharmaceuticals Inc; Eli Lilly and Company; Galderma; GlaxoSmithKline plc; IntraDermTM Pharmaceuticals; Kiniksa Pharmaceuticals; Menlo Therapeutics Inc; Pfizer Inc; Procter & Gamble; Realm-1; Regeneron Pharmaceuticals, Inc
Grant/Research Support: GlaxoSmithKline plc
Linda Stein-Gold, MD
Speakers’ Bureau: LEO Pharma Inc; Pfizer Inc.
Consultant/Advisor: LEO Pharma Inc
Non-faculty: Lou Settembrino; Ankita Patel, PharmD; Sandy Breslow; Leah Johnson; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician